NCT04465032 - Fecal Microbiota Transplantation (FMT) (autologous) vs Fecal Microbiota Transplantation (FMT) (allogenic) & Non-Alcoholic Fatty Liver Disease (NAFLD) / Metabolic dysfunction-associated fatty liver disease (MAFLD)

Background

The gut microbiota is gaining recognition as a contributing factor in metabolic dysfunction-associated steatotic liver disease (MASLD). In this double-blind randomized controlled trial (RCT), researchers assessed the impact of three consecutive fecal microbiota transplantations (FMT) on liver fat accumulation in individuals with MASLD (1)

Study overview

This is a randomized clinical phase IV treatment trial studying Fecal Microbiota Transplantation (FMT) (autologous) vs Fecal Microbiota Transplantation (FMT) (allogenic) at weeks 0, 3, and 6, with follow-up through week 12 in 20 randomized patients with Non-Alcoholic Fatty Liver Disease (NAFLD) / Metabolic dysfunction-associated fatty liver disease (MAFLD) (1)

Primary outcome measures

The effect on consecutive FMT on liver fat accumul…